Dupilumab pregnancy registry finds no higher risk of major birth defects, miscarriage or preterm delivery
Final registry results presented at CHEST 2026 compared dupilumab-exposed pregnancies with unexposed pregnancies in women with asthma or atopic dermatitis, according to the ATS AII Assembly.
“final dupilumab pregnancy registry results showed no higher risk of major birth defects, miscarriage, or preterm delivery”— ATS AII
Final results from a dupilumab pregnancy registry showed no higher risk of major birth defects, miscarriage or preterm delivery, according to a post on X by the American Thoracic Society's AII Assembly account (ATS AII).
The post said the findings were presented at CHEST 2026. The comparison was with unexposed pregnancies in people with asthma or atopic dermatitis.
The post did not give figures, the number of participants, the registry's design or its sponsor. It also did not name a journal. It said only that a full paper is expected, writing: "Keep an eye out for the full paper!"
The information comes from a brief social media summary of a conference presentation rather than a published paper, so detailed results and methods are not yet available from this source.
Original source
“final dupilumab pregnancy registry results showed no higher risk of major birth defects, miscarriage, or preterm delivery”
— ATS AII View the post on X
